| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/21/2007 | WO2007047916A3 Multiclade hiv vaccines |
| 06/21/2007 | WO2007047291A3 Anti-glypican-3 antibody |
| 06/21/2007 | WO2007045477A3 Human antibodies against il-13 and therapeutic uses |
| 06/21/2007 | WO2007038316A3 Human cytomegalovirus latency promoting genes, related virus variants and methods of use |
| 06/21/2007 | WO2007035857A3 Treatment of b cell diseases using anti-germline antibody binding agents |
| 06/21/2007 | WO2007030637A3 Hiv gp120 crystal structure and its use to identify immunogens |
| 06/21/2007 | WO2007027714A3 Engineered anti-il-23 antibodies |
| 06/21/2007 | WO2007020520A3 Antigenic peptides and their use |
| 06/21/2007 | WO2007016340A3 Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| 06/21/2007 | WO2007014238A3 Single dose use of cd20-specific binding molecules |
| 06/21/2007 | WO2007011639A3 Catalytic immunoglobulins |
| 06/21/2007 | WO2006138429A3 Antibodies against hmgb1 and fragments thereof |
| 06/21/2007 | WO2006120230A3 Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| 06/21/2007 | WO2006097530A3 Cat allergen fusion proteins and uses thereof |
| 06/21/2007 | WO2006096701A3 Pharmaceutical liposomal compositions |
| 06/21/2007 | WO2006094974B1 Chemically defined stabiliser composition |
| 06/21/2007 | WO2006078657A3 Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| 06/21/2007 | WO2006063168A3 Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases |
| 06/21/2007 | WO2006003388A8 Compositions and methods for treating inflammatory disorders |
| 06/21/2007 | WO2005005615A3 Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
| 06/21/2007 | WO2004078135A3 LIGANDS THAT BIND TO THE AMYLOID-β PRECURSOR PEPTIDE AND RELATED MOLECULES AND USES THEREOF |
| 06/21/2007 | WO2002100330A9 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 06/21/2007 | US20070143871 Non-human transgenic animal models for hepatocellular carcinoma |
| 06/21/2007 | US20070142421 Pharmaceutical Composition |
| 06/21/2007 | US20070142335 e.g. 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol ; immunology-related disease selected from crohn's disease ulcerative colitis, multiple sclerosis, atopic dermatitis, insulin dependent diabetes mellitus, glomerular nephritis and rejection of a transplanted organ |
| 06/21/2007 | US20070142312 Antigen delivery system |
| 06/21/2007 | US20070141704 Cell fusions and methods of making and using the same |
| 06/21/2007 | US20070141699 Methods of using the signal to transmit and maintain influenza viral and foreign nucleic acid in virus and cells; hemagglutinin (HA) and neuraminidase (NA). |
| 06/21/2007 | US20070141677 Genetic immunization with cationic lipids |
| 06/21/2007 | US20070141653 Method for diagnosing infectious diseases |
| 06/21/2007 | US20070141643 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 06/21/2007 | US20070141617 Enveloped virus vaccine and method for production |
| 06/21/2007 | US20070141590 Modulators of tissue regeneration |
| 06/21/2007 | US20070141578 LuxO-sigma54 interactions and methods of use |
| 06/21/2007 | US20070141145 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
| 06/21/2007 | US20070141134 Shielded micelles for polynucleotide delivery |
| 06/21/2007 | US20070141088 Glucan-based vaccines |
| 06/21/2007 | US20070141087 Compounds and methods for diagnosis of tuberculosis |
| 06/21/2007 | US20070141086 Use of antibiotics as vaccine adjuvants |
| 06/21/2007 | US20070141085 Recombinant protective protein from Streptococcus pneumoniae |
| 06/21/2007 | US20070141084 Polysaccharide-protein conjugate vaccines |
| 06/21/2007 | US20070141083 Use of a single-cell protein material |
| 06/21/2007 | US20070141082 Cell surface expression vector of parvovirus antigen and microorganisms transformed thereof |
| 06/21/2007 | US20070141081 Proteins for use as vaccine to prevent dengue virus infection; immunotherapy; high serotype-specificity to be used in humans |
| 06/21/2007 | US20070141080 Treating severe acute respiratory syndrome |
| 06/21/2007 | US20070141079 Antibody production in farm animals |
| 06/21/2007 | US20070141078 Monovalent; low dose of egg-derived influenza virus antigen from an influenza virus strain associated with or having the potential to cause a pandemic outbreak (e.g. H5N1antigen), with an oil in water emulsion adjuvant of an oil, alpha-tocopherol, and an emulsifier; can be made quickly in pandemic |
| 06/21/2007 | US20070141077 Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 06/21/2007 | US20070141076 Antigen fragments for the diagnosis of Toxoplasma gondii |
| 06/21/2007 | US20070141075 Plasmodium vivax blood stage antigens, PVESP-1, antibodies and diagnostic assays |
| 06/21/2007 | US20070141074 Agents for the inhibition of virus replication through regulation of protein folding |
| 06/21/2007 | US20070141073 Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same |
| 06/21/2007 | US20070141072 Use of multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes |
| 06/21/2007 | US20070141071 Hot melt coating by direct blending and coated substrates |
| 06/21/2007 | US20070141070 Methods and compositions for needleless delivery of antibodies |
| 06/21/2007 | US20070141069 Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
| 06/21/2007 | US20070141068 Methods for the treatment of carcinoma |
| 06/21/2007 | US20070141067 Targeted cancer therapy |
| 06/21/2007 | US20070141066 Method for Diagnosing, Prognosing and Treating Glioma |
| 06/21/2007 | US20070141065 capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, edema, inflammation |
| 06/21/2007 | US20070141064 Fully human hybridoma fusion partner cell lines |
| 06/21/2007 | US20070141063 Peptide having ability to activate cancer-related gene |
| 06/21/2007 | US20070141062 Control of proliferation and apoptosis in cancer cells |
| 06/21/2007 | US20070141061 Protein involved in carcinoma |
| 06/21/2007 | US20070141060 Hmgb1 protein inhibitors for the regulation of smooth muscle cells and endothelial cells profileration |
| 06/21/2007 | US20070141059 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 06/21/2007 | US20070141058 Method of correcting immunopathological reactions and a medicament |
| 06/21/2007 | US20070141057 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/21/2007 | US20070141056 Growth factor homolog zvegf3 |
| 06/21/2007 | US20070141055 Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes |
| 06/21/2007 | US20070141054 Anti-A33 antibody that specifically binds to an A33 antigen; a preventive or therapeutic agent for diseases due to A33-expressing cells, and in particular, a molecule that is also useful as a malignant tumor remedy for patients with A33 polymorphism, are provided |
| 06/21/2007 | US20070141053 Treatment of inflammatory respiratory diseases |
| 06/21/2007 | US20070141052 Fc region variants |
| 06/21/2007 | US20070141051 Nucleic acid encoding cytokine receptor zcytor17 |
| 06/21/2007 | US20070141050 Using epitopic peptide linked to solid support to screen for anti-human leukocyte antigen (HLA) reactive antibodies in bodily fluids; prognostic tool in determining organ/tissue rejection; organ transplantation |
| 06/21/2007 | US20070141049 Bivalent IgY antibody constructs for diagnostic and therapeutic applications |
| 06/21/2007 | US20070141048 Using multiplex overlap-extension reverse transcriptase polymerase chain reaction to combine two or more nucleotide sequences encoding domains or subunits of heteromeric protein in a single reaction |
| 06/21/2007 | US20070141047 Feline immunoglobulin e proteins and compositions thereof |
| 06/21/2007 | US20070141042 Methods for the treatment and prevention of diseases of biological conduits |
| 06/21/2007 | US20070141027 Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| 06/21/2007 | US20070141026 Immunotherapy in cancer treatment |
| 06/21/2007 | US20070141025 Compositions and methods for cancer immunotherapy |
| 06/21/2007 | US20070141024 Mammalian cytokine; reagents and methods |
| 06/21/2007 | US20070140970 Cell targeting conjugates |
| 06/21/2007 | US20070140968 Method for determining botulinum potency |
| 06/21/2007 | US20070140966 Multivalent immunoglobulin-based bioactive assemblies |
| 06/21/2007 | US20070140965 Methods to ameliorate and image angioplasty-induced vascular injury |
| 06/21/2007 | US20070140964 Cytokine receptor zcytor17 multimers |
| 06/21/2007 | US20070140963 Cytokine receptor zcytor17 multimers |
| 06/21/2007 | CA2636139A1 Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| 06/21/2007 | CA2633956A1 Binding proteins specific for insulin-like growth factors and uses thereof |
| 06/21/2007 | CA2633594A1 Means and methods for the treatment of tumorous diseases |
| 06/21/2007 | CA2633501A1 Immunoglobulins directed against nogo |
| 06/21/2007 | CA2633399A1 Therapeutic vaccine |
| 06/21/2007 | CA2633211A1 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 06/21/2007 | CA2633038A1 Anti-mn antibodies and methods of using same |
| 06/21/2007 | CA2633008A1 Vaccine compositions comprising a saponin adjuvant |
| 06/21/2007 | CA2632983A1 Biological materials and uses thereof |
| 06/21/2007 | CA2632822A1 A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| 06/21/2007 | CA2631938A1 Anti-il-17 antibodies |